Results 31 to 40 of about 848 (166)

Hyalase in Dermatology: Applications Beyond Filler Management. [PDF]

J Cosmet Dermatol
ABSTRACT Background Hyaluronic acid (HA) is a key extracellular matrix component in the skin. Hyaluronidase is an enzyme that breaks down HA into monosaccharides. The FDA has approved this enzyme for hypodermoclysis, drug absorption enhancement, and subcutaneous urography.
Hasanzadeh S, Farokh P, Hosseini GS, Abbasian M, Etesami I, Zaresharifi S, Dadkhahfar S.   +6 more
europepmc   +2 more sources

Granulomatous variant of scleromyxedema successfully treated with topical ruxolitinib, dapsone and intravenous immunoglobulin [PDF]

JAAD Case Reports, 2023
Donglin Zhang, BA, Kimberly Sable, MD, Allison Miller, MD, Molly Hinshaw, MD, Timothy Schmidt, MD, Bridget E. Shields, MD   +5 more
doaj   +2 more sources

Clonal disorders of clinical significance. A concept with important therapeutic implications. [PDF]

J Eur Acad Dermatol Venereol
Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 5, Page 891-892, May 2025.
Lipsker D.
europepmc   +2 more sources

Successful treatment of scleromyxedema with dupilumab: A case report [PDF]

JAAD Case Reports
Abdulelah Alghamdi, MBBS, Abdulrahman Alfawzan, MBBS, Khalid Aburas, MBBS, Nedhal Ayoub, MD, Mohammad Almohideb, MD   +4 more
doaj   +2 more sources

Paraneoplastic atypical scleromyxedema with advanced gastric cancer

JAAD Case Reports, 2017
Se Jin Oh, Jong Hee Lee, Seung Hwan Oh
exaly   +3 more sources

Scleromyxedema

Current Opinion in Rheumatology, 2014
To synthesize the current known data on pathogenesis and treatment of scleromyxedema. This review will also highlight the clinical presentation, systemic features and outcomes and distinguishing features between scleromyxedema and scleroderma, as a common mimic.Most recent publications have focused on describing treatment responses with novel therapies,
Bogner, Ryan R., Wetter, David A., Dingli, David   +2 more
openaire   +5 more sources

Plasma cell-directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema. [PDF]

J Eur Acad Dermatol Venereol
In severe forms of monoclonal gammapathy associated with scleromyxoedema with dermatoneuro syndrome and/or cardiac involvement, deep and durable responses allowing IVIG withdrawal could be achieved using anti‐plasma cell therapy, including Imids, anti‐CD38 or proteasome inhibitors. Abstract Background Scleromyxedema (SM) is a rare skin disorder related
Theves F, Lahuna C, Mahévas T, Harel S, Royer B, Lemiale V, Brignier A, Parquet N, Jachiet M, Bouaziz JD, Elessa D, Arnulf B, Talbot A.   +12 more
europepmc   +2 more sources

Scleromyxedema Without Monoclonal Gammopathy Treated with Intravenous Immunoglobulins [PDF]

, 2021
Scleromyxedema is a generalized cutaneous mucinosis that may cause internal damage. This condition is frequently associated with monoclonal gammopathy. However, its physiopathological implications remains uncertain.
Letzelter, Mathilde, Grimaux, Xavier
core   +2 more sources

Lichen myxedematosus: a rare group of cutaneous mucinosis [PDF]

Anais Brasileiros de Dermatologia
: Cutaneous mucinoses are a heterogeneous group of dermatoses in which excess deposition of mucin in the dermis gives the skin a waxy appearance, with papules and plaques that can vary from self-healing mucinosis to even disrupting the normal shape of a ...
Ramiro Eugenio Cárdenas-Gonzalez, Maira Elizabeth Herz Ruelas, Jorge Ocampo Candiani   +2 more
doaj   +2 more sources

Localized eruption of glabella and eyebrows [PDF]

JAAD Case Reports
Celestina Okoye, MD, Kai Brady, BS, Jennifer Shastry, MD   +2 more
doaj   +2 more sources